Skip to main content

ANGLE PLC has opened up "a major market opportunity" with breast cancer partnership

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland joins Thomas Warner from Proactive after announcing a development partnership with BioView.

The partnership will see the two firms develop to create a circulating tumour cell (CTC) HER2 assay for breast cancer that could ultimately enable hospitals worldwide to access technology that measures HER2 status in breast cancer patients.

Newlands says it has opened up "a major market opportunity" with the partnership.

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/angle-plc-has-opened-up-a-major-market-opportunity-with-breast-cancer-partnership-730080164

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  266.32
-2.14 (-0.80%)
AAPL  308.82
+3.83 (1.26%)
AMD  467.51
+17.92 (3.99%)
BAC  51.80
+0.31 (0.60%)
GOOG  379.38
-4.09 (-1.07%)
META  610.26
+2.88 (0.47%)
MSFT  418.57
-0.52 (-0.12%)
NVDA  215.33
-4.18 (-1.90%)
ORCL  192.08
+2.31 (1.22%)
TSLA  426.01
+8.16 (1.95%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.